NBTX - יחס חוב להיוון בספרים Nanobiotix S.A.

The development of Nanobiotix S.A. (NBTX) relies on the success of nanopharmaceuticals for enhancing tumor radiation, while the 0.00 metric accounts for European regulatory risks. This price chart on the GURU.Markets platform complements data on the business model, where production and testing are outsourced to third-party contractors. Operations are rounded out by the implementation of ESG principles in laboratories, adherence to research ethics, and management transparency.

This ratio determines the proportion of borrowed funds relative to equity on the balance sheet, measuring the issuer's financial leverage and overall solvency. By analyzing the historical trend of the debt-to-book capitalization ratio, an investor assesses the margin of safety for Nanobiotix S.A. while awaiting new strategic partnerships for the NBTXR3 platform, as the asset's market value currently prices in existing interim results.